



Grant recipient

Dr Patrice Rosengrave
University of Otago
Pathology

patrice.rosengrave@otago.ac.nz
03 364 0649
2 Riccarton Ave, Christchurch, New Zealand
8011

Grant details

GRANT TYPE	Travel Grant	FUNDING ROUND	2018 Travel Grant
GRANT REFERENCE	002	GRANT AMOUNT	\$2,000

Final report

1. Scientific Assessing Committee report

I attended the ANZICS (Australia and New Zealand Intensive Care Society) - 21st Annual Meeting on Clinical Trials in Intensive Care, in Noosa Australia this March.

Assoc Pro Carr and myself commenced our pilot study - "double-blinded placebo controlled clinical trial looking at the effects of intravenous vitamin C on patients with severe sepsis in the Christchurch Public Intensive Care Unit.

Additionally in 2018 I have commenced the following study (CMRF funded) "The effect of vitamin C administration on long-term physical and mental health outcomes of survivors of sepsis post ICU admission".

Therefore it was most timely to be able to attend this meeting, and for me to present some preliminary data.

At this conference I gave a 10 minute talk entitled "Vitamin C administration in severe sepsis: a double-blinded placebo-controlled randomised pilot trial" I presented our overall study aim, and baseline demographic data for the septic patients (n=15) that have been enrolled in our study. Post my talk I was able to engage with fellow researchers and answer questions pertaining to our clinical trial.

Additionally, I was able to attend other talks whereby other clinical trials have measured quality of life measures on survivors of critical illness (e.g. the effects of long-term ventilation of quality of life post ICU admission).

Two other clinical trials commenced in 2018 in New Zealand looking at the effects of vitamin C on patient outcomes for those patients that have been admitted to an Intensive Care Unit. It was most beneficial to chat to these researchers from Wellington post my presentation. It was also good to chat to the coordinators of these trials to find that they were coming across the same hurdles and challenges that we are also facing in our clinical trial.



On a professional level it also beneficial to talk to other research scientists and clinicians in relation to future collaborative research grants, and I am most grateful to

have been given this opportunity to engage with clinicians and researchers in this community, which widen my professional network.

3. Feedback